MarketCap
Facebook
X
TelegramAzurRx BioPharma, Inc. ROA Ratio 2011-2026 | AZRX
Annual ROA Ratio AzurRx BioPharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -252799694827.9 | -170.48 | -181.19 | -202.5 | -216.05 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -170.48 | -252799694827.9 | -50559939119.62 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
23.54 | $ 16.62 | 1.47 % | $ 3.96 B |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ANI Pharmaceuticals
ANIP
|
-1.44 | $ 77.07 | 1.27 % | $ 1.49 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | $ 20.12 | -0.2 % | $ 2.54 B | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.81 | 2.62 % | $ 4.42 M |  China |
 |
Graybug Vision
GRAY
|
-217.51 | - | -11.23 % | $ 9.65 M | USA |
 |
Axsome Therapeutics
AXSM
|
-26.55 | $ 164.87 | 0.5 % | $ 8.2 B | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.72 | 0.13 % | $ 1.11 B |  Canada |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-50.64 | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
4.59 | $ 61.12 | 4.43 % | $ 11.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-634.44 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.38 | -1.99 % | $ 1.39 B | Britain |
 |
Cabaletta Bio
CABA
|
-26.68 | $ 3.42 | 5.08 % | $ 3.99 M | USA |
 |
BridgeBio Pharma
BBIO
|
-78.3 | $ 67.08 | 3.95 % | $ 12.8 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Codexis
CDXS
|
-43.81 | $ 1.1 | 11.73 % | $ 80.7 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
-55.94 | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 1.8 | 8.79 % | $ 169 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-73.85 | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-74.39 | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-273.86 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-273.86 | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
-37.95 | $ 26.34 | 1.93 % | $ 705 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Certara
CERT
|
-0.1 | $ 7.25 | 0.14 % | $ 1.16 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Champions Oncology
CSBR
|
14.53 | $ 6.05 | 0.83 % | $ 82.6 M | USA |